HCPCS Code Applications and Approvals: January 2024
Quarterly archive · CMS Level II HCPCS52 coding decisions took effect January 1, 2024
These are the Centers for Medicare and Medicaid Services (CMS) Level II HCPCS drug coding decisions from the Third Quarter 2023 coding cycle, which took effect January 1, 2024.
For the newest decisions, see the current HCPCS code applications and approvals.
CMS Level II HCPCS Drug Coding Decisions
Does not include Q4 skin repair and wound codes.
How to Read This Table
- Action
- CMS decision on the application — establish a new code, revise an existing descriptor, reinstate a code, or discontinue one. See the glossary.
- Code Change
- Where CMS retires a code in favor of another, the new code shows the code it replaces and the retired code shows its replacement.
- 505(b)(2) and Biosimilar
- Tags beside the drug name mark products approved under the FDA 505(b)(2) pathway and biosimilars.
- Effective
- First date of service on which the code may be billed. Codes effective before this quarter reflect retroactive establishment; codes effective after it are decisions CMS scheduled for a later quarter.
January 2024
| HCPCS | Drug & Descriptor | Company | Code Change | Action | Effective |
|---|---|---|---|---|---|
| A9608 | POSLUMA, flotufolastat F18 Flotufolastat f18, diagnostic, 1 millicurie | Blue Earth Diagnostics, Inc. | — | Establish | |
| A9609 | Fludeoxyglucose F18 Fludeoxyglucose f18 up to 15 millicuries | RefleXion Medical Inc. | — | Establish | |
| J0184 | BARHEMSYS 505(b)(2) Injection, amisulpride, 1 mg | Eagle Pharmaceuticals, Inc. | — | Establish | |
| J0217 | LAMZEDE Injection, velmanase alfa-tycv, 1 mg | Chiesi USA, Inc. Intravenous | — | Establish | |
| J0391 | Artesunate 505(b)(2) Injection, artesunate, 1 mg | — | — | Establish | |
| J0402 | ABILIFY ASIMTUFII Injection, aripiprazole (abilify asimtufii), 1 mg | Otsuka America Pharmaceutical, Inc. Intramuscular | — | Establish | |
| J0576 | BRIXADI 505(b)(2) Injection, buprenorphine extended-release (brixadi), 1 mg | Braeburn Inc. | — | Establish | |
| J0688 | Cefazolin Sodium (Hikma) Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | — | — | Establish | |
| J0873 | Daptomycin (Xellia) 505(b)(2) Injection, daptomycin (xellia) not therapeutically equivalent to j0878, 1 mg | — | — | Establish | |
| J1105 | IGALMI 505(b)(2) Dexmedetomidine, oral, 1 mcg | Bioxcel Therapeutics | — | Establish | |
| J1304 | QALSODY Injection, tofersen, 1 mg | Biogen, Inc. Intrathecal | — | Establish | |
| J1412 | ROCTAVIAN Injection, valoctocogene roxaparvovec-rvox, per mL, containing nominal 2 × 10^13 vector genomes | BioMarin Intravenous | — | Establish | |
| J1413 | Elevidys Injection, delandistrogene moxeparvovec-rokl, per therapeutic dose | Sarepta Therapeutics, Inc. | — | Establish | |
| J1596 | Glycopyrrolate Injection, glycopyrrolate, 0.1 mg | — | — | Establish | |
| J1939 | Bumetanide 505(b)(2) Injection, bumetanide, 0.5 mg | — | — | Establish | |
| J2404 | Nicardipine 505(b)(2) Injection, nicardipine, 0.1 mg | — | — | Establish | |
| J2508 | ELFABRIO Injection, pegunigalsidase alfa-iwxj, 1 mg | Chiesi USA, Inc. Intravenous | — | Establish | |
| J2679 | Fluphenazine Hcl Injection, fluphenazine hcl, 1.25 mg | — | — | Establish | |
| J2799 | UZEDY 505(b)(2) Injection, risperidone (uzedy), 1 mg | Teva Pharmaceuticals Industries Ltd. (Teva) Subcutaneous | — | Establish | |
| J3401 | VYJUVEK Beremagene geperpavec-svdt for topical administration, containing nominal 5 x 10^9 pfu/ml vector genomes, per 0.1 ml | Krystal Biotech Topical | — | Establish | |
| J3425 | Hydroxocobalamin 505(b)(2) Injection, hydroxocobalamin, intramuscular, 10 mcg | — | — | Establish | |
| J9052 | Carmustine (Accord) 505(b)(2) Injection, carmustine (accord), not therapeutically equivalent to j9050, 100 mg | — | — | Establish | |
| J9072 | Cyclophosphamide 505(b)(2) Injection, cyclophosphamide, (dr. reddy's), 5 mg | Dr. Reddy's Laboratories, Inc. Intravenous | — | Establish | |
| J9160 | ONTAK Injection, denileukin diftitox, 300 micrograms | Citius Pharmaceuticals, Inc. | — | Discontinue | |
| J9172 | Docetaxel Injection 505(b)(2) Injection, docetaxel (ingenus) not therapeutically equivalent to j9171, 1 mg | Ingenus Intravenous | — | Establish | |
| J9255 | Methotrexate Injection Injection, methotrexate (accord) not therapeutically equivalent to j9250 or j9260, 50 mg | Accord Healthcare Inc. Intravenous | — | Establish | |
| J9258 | Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) 505(b)(2) Injection, paclitaxel protein-bound particles (teva) not therapeutically equivalent to j9264, 1 mg | Teva Pharmaceuticals Industries Ltd. (Teva) Intravenous | — | Establish | |
| J9286 | Columvi Injection, glofitamab-gxbm, 2.5 mg | Genentech Intravenous | — | Establish | |
| J9321 | EPKINLY Injection, epcoritamab-bysp, 0.16 mg | Genmab and AbbVie Subcutaneous | — | Establish | |
| J9324 | Pemrydi RTU, Pemetrexed 505(b)(2) Injection, pemetrexed (pemrydi rtu), 10 mg | Amneal Pharmaceuticals | — | Establish | |
| J9333 | RYSTIGGO Injection, rozanolixizumab-noli, 1 mg | UCB, Inc. Subcutaneous | — | Establish | |
| J9334 | VYVGART Hytrulo Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc | Argenx Subcutaneous | — | Establish | |
| Q4225 | DermaBind TL Amniobind or dermabind tl, per square centimeter | Health Tech Wound Care | — | Revise | |
| Q4279 | VENDAJE AC Vendaje ac, per square centimeter | BioStem Technologies, Inc. | — | Establish | |
| Q4287 | DermaBind DL Dermabind dl, per square centimeter | Health Tec Wound Care | — | Establish | |
| Q4288 | DermaBind CH Dermabind ch, per square centimeter | Health Tec Wound Care | — | Establish | |
| Q4289 | RevoShield + Amniotic Barrier Revoshield + amniotic barrier, per square centimeter | 4Front Strategic Partners, Surgenex, LLC | — | Establish | |
| Q4290 | Membrane Wrap-Hydro Membrane wrap-hydro, per square centimeter | BioLab Sciences | — | Establish | |
| Q4291 | Lamellas XT Lamellas xt, per square centimeter | Keyport Management | — | Establish | |
| Q4292 | Lamellas Lamellas, per square centimeter | Keyport Management | — | Establish | |
| Q4293 | Acesso DL Acesso dl, per square centimeter | Dynamic Medical Services LLC, Surgenex | — | Establish | |
| Q4294 | Amnio Quad-Core Amnio quad-core, per square centimeter | Stability Biologics | — | Establish | |
| Q4295 | Amnio Tri-Core Amnio tri-core amniotic, per square centimeter | Stability Biologics | — | Establish | |
| Q4296 | Rebound Matrix Rebound matrix, per square centimeter | Sequence LifeScience, Inc. | — | Establish | |
| Q4297 | Emerge Matrix Emerge matrix, per square centimeter | Sequence LifeScience, Inc. | — | Establish | |
| Q4299 | AmnioCore Pro+ Amnicore pro+, per square centimeter | Stability Biologics | — | Establish | |
| Q4300 | Acesso TL Acesso tl, per square centimeter | Dynamic Medical Services LLC DBA Acesso Biologics, Surgenex | — | Establish | |
| Q4301 | Activate Matrix Activate matrix, per square centimeter | — | — | Establish | |
| Q4302 | Complete ACA Complete aca, per square centimeter | Samaritan Biologics LLC | — | Establish | |
| Q4303 | Complete AA Complete aa, per square centimeter | Samaritan Biologics LLC | — | Establish | |
| Q4304 | GRAFIX PLUS Grafix plus, per square centimeter | Smith and Nephew | — | Establish | |
| Q5132 | ABRILADA Biosimilar Injection, adalimumab-afzb (abrilada), biosimilar, 10 mg | Pfizer, Inc. Subcutaneous | — | Establish |
No coding decisions match those filters.
Source: CMS HCPCS application summaries, Third Quarter 2023 coding cycle (PDF) . Data current as of October 7, 2026.
Other Quarters
Decisions per quarter since July 2022 · select a bar to open that quarter
